Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts

Interleukin (IL-) 6 is a key factor in the inflammatory processes of rheumatoid arthritis. Several biologic agents target the IL-6 signaling pathway, including sarilumab, a monoclonal antibody that blocks the IL-6 receptor and inhibits IL-6-mediated cis- and trans-signaling. A careful analysis of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Klinder, Annett, Waletzko-Hellwig, Janine, Sellin, Marie-Luise, Seyfarth-Sehlke, Anika, Wolfien, Markus, Prehn, Franziska, Bader, Rainer, Jonitz-Heincke, Anika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318132/
https://www.ncbi.nlm.nih.gov/pubmed/35890286
http://dx.doi.org/10.3390/pharmaceutics14071390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318132/
https://www.ncbi.nlm.nih.gov/pubmed/35890286
http://dx.doi.org/10.3390/pharmaceutics14071390

Ejemplares similares